Drugs.com - Clinical Trials

Cortex’s AMPAKINE Compound, CX717, Achieves Primary Endpoints in Second Phase IIa Respiratory Depression Study in Germany

Mon, 06 Oct 2008 19:30:52 GMT

CX717 Prevents Opioid-Induced Respiratory Depression While Maintaining Analgesia IRVINE, Calif., Oct. 6, 2008--(BUSINESS WIRE)--Cortex Pharmaceuticals, Inc. (NYSE Alternext US (COR)) reported that top-line data from its second Phase IIa study in...

VIVUS Announces the Weight Loss Effects of Qnexa in Type 2 Diabetes

Mon, 06 Oct 2008 19:15:34 GMT

Presentation at the Obesity Society Annual Scientific Meeting Shows Weight Loss of 17 Pounds in 28 Weeks MOUNTAIN VIEW, Calif., Oct. 6, 2008--(BUSINESS WIRE)--VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and...

Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed

Mon, 06 Oct 2008 19:00:10 GMT

TAK-390MR Data Presented at the American College of Gastroenterology Annual Meeting ORLANDO, Fla., Oct. 6 /PRNewswire/ -- Combined results from two Phase 3 studies presented at the American College of Gastroenterology Annual Scientific Meeting (ACG)...

Video: COPD Landmark Trial UPLIFT Proves Tiotropium Sustains Lung Function Improvements Over Four Years and Improves Survival Rate

Mon, 06 Oct 2008 18:55:22 GMT

Results of 5,993 patient study UPLIFT(R) (Understanding Potential Long-term Impacts on Function with Tiotropium) presented today at European BERLIN, Oct. 6 /PRNewswire/ -- Results of the UPLIFT(R) trial, presented today at the European Respiratory...

Salix Presents New Phase II Data Evidence Demonstrating the Clinical Utility of Rifaximin in Irritable Bowel Syndrome (IBS)

Mon, 06 Oct 2008 17:05:31 GMT

Results Presented at American College of Gastroenterology Annual Meeting Demonstrate Quality of Life Benefits and IBS Symptom Severity as Predictor of Clinical Response ORLANDO, Fla., Oct. 6, 2008--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd....

Provectus Lead Investigator Professor John F. Thompson Gives Update on PV-10 Phase 2 Study

Mon, 06 Oct 2008 16:35:09 GMT

PV-10 Treatment Was Well Tolerated by First 20 Patients Response of Treated Lesions May Be a Good Predictor of Long-Term Outcome KNOXVILLE, Tenn., Oct. 6, 2008--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT), a development-stage...

Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin and Tarceva as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer

Mon, 06 Oct 2008 15:10:28 GMT

South San Francisco, Calif. and Melville, New York -- October 5, 2008 -- Genentech, Inc. (NYSE: DNA) and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) today announced that a randomized Phase III study (BeTa Lung) evaluating Avastin® (bevacizumab) in...

Bayer Reports Progress in Clinical Program for Riociguat

Mon, 06 Oct 2008 15:05:17 GMT

www.bayerhealthcare.com.www.bayerscheringpharma.de.www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer Schering Pharma is a worldwide...

Salix Presents New Phase II Data Evidence Demonstrating the Clinical Utility of Rifaximin in Irritable Bowel Syndrome (IBS)

Mon, 06 Oct 2008 14:55:13 GMT

Results Presented at American College of Gastroenterology Annual Meeting Demonstrate Quality of Life Benefits and IBS Symptom Severity as Predictor of Clinical Response ORLANDO, FLA., October 6, 2008 – Salix Pharmaceuticals, Ltd....

Cimzia (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients

Mon, 06 Oct 2008 14:20:56 GMT

More than 60 percent of moderate to severe patients achieved endoscopic response and more than 40 percent achieved endoscopic remission at Week 10 in data from a 54-week open-label study presented at the American College of Gastroenterology (ACG)...

Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting

Mon, 06 Oct 2008 14:10:44 GMT

PLYMOUTH MEETING, Pa., Oct. 6 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) today reported data from its second Phase 1 clinical trial of trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and...

Cortex's Ampakine Compound, CX717, Achieves Primary Endpoints in Second Phase IIa Respiratory Depression Study in Germany

Mon, 06 Oct 2008 14:00:42 GMT

CX717 Prevents Opioid-Induced Respiratory Depression While Maintaining Analgesia IRVINE, Calif.--(BUSINESS WIRE)--Cortex Pharmaceuticals, Inc. (NYSE Alternext US (COR)) reported that top-line data from its second Phase IIa study in opioid-induced...

Shire Announces Results from a Multidisciplinary Analysis of the Drug Release Profiles of LIALDA (mesalamine) and Asacol (mesalamine) for the Treatment of Ulcerative Colitis (UC) at the American College of Gastroenterology (ACG) Meeting

Mon, 06 Oct 2008 14:00:15 GMT

PHILADELPHIA, Oct. 6 /PRNewswire-FirstCall/ -- Shire plc (NASDAQ:SHPGY) , the global specialty biopharmaceutical company, announced the results from a multidisciplinary analysis of in vitro and in vivo data of LIALDA(R) (mesalamine) versus Asacol(R)...

Dendreon Announces Interim Data From Phase 3 Provenge IMPACT Trial

Mon, 06 Oct 2008 13:55:02 GMT

- Conference Call Scheduled for 9:00 AM ET Today - SEATTLE, Oct. 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ:DNDN) announced today that it has completed the planned interim analysis of the Phase 3, randomized, double-blind,...

Dendreon Announces Interim Data from Phase 3 Provenge IMPACT Trial

Mon, 06 Oct 2008 13:45:41 GMT

-- Conference Call Scheduled for 9:00 AM ET Today -- SEATTLE, October 6, 2008 - Dendreon Corporation (Nasdaq: DNDN) announced today that it has completed the planned interim analysis of the Phase 3, randomized, double-blind, placebo-controlled...

Orexigen Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave

Mon, 06 Oct 2008 13:45:39 GMT

- Improved Pharmacokinetic Characteristics of Naltrexone SR Associated with Better Tolerability in Clinical Trials - PHOENIX, Oct. 6 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (NASDAQ:OREX) , a biopharmaceutical company focused on the...

Genta Updates Progress of its Phase 3 Trial of Genasense in Patients with Advanced Melanoma AGENDA Trial Expected to Complete Accrual Early 2009

Mon, 06 Oct 2008 13:45:25 GMT

BERKELEY HEIGHTS, NJ – October 6, 2008 – Genta Incorporated (OTCBB: GNTA) announced the presentation of a progress update from the Company’s ongoing Phase 3 trial of Genasense® (oblimersen sodium) Injection, Genta’s lead oncology product,...

COPD Landmark UPLIFT trial proves tiotropium significantly reduces risk of death, improves quality of life, sustains lung function improvements over four years

Mon, 06 Oct 2008 13:40:44 GMT

Results of 5,993 patient study UPLIFT(R) (Understanding Potential Long-term Impacts on Function with Tiotropium) presented today at European Respiratory Society Annual Congress, and published online in New England Journal of Medicine BURLINGTON,...

CombinatorX Announces Top-Line Results from Phase 2b Study of Synavive (CRx-102) for Knee Osteoarthritis

Mon, 06 Oct 2008 13:35:04 GMT

Paul Kidwell 617.296.3854: Office 617.680.1088: Mobile Investor Conference Call Scheduled for Today at 8:30 am EDT CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX), today announced preliminary top-line results from...

New Findings Show Efficacy of Remicade Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study

Mon, 06 Oct 2008 13:20:33 GMT

Data from SONIC Trial Showed REMICADE Therapy is More Likely to Induce Steroid-Free Remission and Mucosal Healing Compared with Standard Immunomodulator, Azathioprine ORLANDO, Fla., Oct. 6 /PRNewswire/ -- Data presented for the first time from the...

MaxCyte to Present at AABB Annual Meeting & TXPO 2008 in Montreal, Quebec, Canada

Sat, 04 Oct 2008 01:56:12 GMT

"Peripheral Blood Mononuclear Cells Engineered with mRNA Encoding Chimeric Tumor Antigen Receptor for Cancer Therapy" AND "Use of Platelets as Therapeutic Delivery Vehicles" GAITHERSBURG, Md., Oct. 3 /PRNewswire-USNewswire/ -- MaxCyte, Inc., a...

New Chemotherapy ‘Cures’ Early Testicular Cancer

Sat, 04 Oct 2008 01:56:10 GMT

BETHESDA, Md., Oct. 3, 2008-A single injection of carboplatin – a chemotherapy drug commonly used to treat ovarian and lung cancer – can replace radiotherapy to cure a common type of testicular cancer, according to results presented at...

New Publication Shows Cleviprex Provides More Precise Blood Pressure Control in Cardiac Surgery Patients

Sat, 04 Oct 2008 01:55:46 GMT

ECLIPSE Data Published in Anesthesia and Analgesia FOR U.S. AUDIENCES ONLY PARSIPPANY, N.J., Oct. 3, 2008--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced that ECLIPSE, the largest safety program to date comparing...

Pharmaxis Research Programs Highlighted at European Respiratory Society Congress

Sat, 04 Oct 2008 01:55:15 GMT

SYDNEY, Australia, Oct. 3 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis has announced that researchers will present 12 abstracts from its respiratory disease program at the 2008 European Respiratory Society Congress (ERS) being...

Provectus Lead Investigator Professor John F. Thompson Presents at “Perspectives in Melanoma XII” Conference

Thu, 02 Oct 2008 16:55:50 GMT

PV-10 Treatment for Metastatic Melanoma Well-Tolerated by Patients Evidence of “Bystander Effect” Observed in Phase 1 Trial KNOXVILLE, Tenn., Oct. 2, 2008--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a...

Journal: Scientists Identify Successful 'Anti' Antibiotic That May Help Curb Rising Staph Infections

Thu, 02 Oct 2008 14:10:56 GMT

ALBANY, Ore., Oct. 2 /PRNewswire/ -- For the second year in a row, students and athletes across the country are being hit by antibiotic resistant staph infections known as MRSA. In just over a week, two high school football players have died from...

Access Pharmaceuticals Presents New Data on the Company's Angiolix Therapeutic Monoclonal Antibody

Thu, 02 Oct 2008 13:35:11 GMT

Data Indicate Dual Modes of Action and Synergy with Chemotherapy DALLAS, Oct. 2 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC:ACCP) (BULLETIN BOARD: ACCP) presented data this week from preclinical studies on Angiolix showing that by...

Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society

Thu, 02 Oct 2008 12:50:23 GMT

Data support the therapeutic potential of Amylin's integrated neurohormonal approach to obesity pharmacotherapy SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced that new data for its pipeline...

A.P. Pharma Announces Positive Phase 3 Results with APF530 in the Prevention of CINV

Wed, 01 Oct 2008 20:50:29 GMT

Company on Track to Submit NDA in the Fourth Quarter of 2008 Conference Call Begins Today at 9:00 A.M. Eastern Time REDWOOD CITY, Calif.--(BUSINESS WIRE)--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, announced today positive...

Tranzyme Pharma Announces Positive Phase IIb Results with Its Ghrelin Agonist, TZP-101, for Postoperative Ileus (POI)

Wed, 01 Oct 2008 20:45:51 GMT

Phase III Initiation Targeted Q1 2009 RESEARCH TRIANGLE PARK, N.C., Oct. 1, 2008--(BUSINESS WIRE)--Tranzyme Pharma today announced positive Phase IIb results for its first-in-class, highly potent and selective ghrelin agonist, TZP-101, for...

Apthera Announces Optimal Dose and Schedule of NeuVax for Phase III Clinical Trial in Breast Cancer

Wed, 01 Oct 2008 20:25:42 GMT

SCOTTSDALE, Ariz., Oct. 1, 2008--(BUSINESS WIRE)--Apthera, Inc. announced the optimized dose and schedule for its lead drug, NeuVax, in treating early-stage breast cancer patients to be used in Phase III clinical trials. Dr. George Peoples, Deputy...

Idera Pharmaceuticals Announces Preliminary Data from Phase 2a Clinical Study of IMO-2055 Monotherapy in Renal Cell Carcinoma

Wed, 01 Oct 2008 20:05:48 GMT

CAMBRIDGE, Mass., Oct, 1, 2008--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced preliminary data from the first part of a Phase 2 clinical study conducted by the Company of IMO-2055 monotherapy in patients with...

Watson Announces Positive Data for RAPAFLO(silodosin), Its Investigational Product for BPH, at Regional AUA Conferences

Wed, 01 Oct 2008 19:05:17 GMT

- Results demonstrate the efficacy, safety and tolerability of RAPAFLO(TM) alone or in combination with treatments for erectile dysfunction - CORONA, Calif., Sept. 29 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI) , a leading...

Dicerna Pharmaceuticals Announces Preclinical Findings Highlighting Novel Approach to Maximizing Dicer-Substrate Small Interfering RNAs (DsiRNAs) in Rheumatoid Arthritis; Data Appear Published by Molecular Therapy

Wed, 01 Oct 2008 18:50:50 GMT

CAMBRIDGE, Mass., Oct, 1, 2008--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (www.dicerna.com), a second generation RNA interference company developing novel therapeutics utilizing proprietary Dicer Substrate Technology™, announced today a paper...

Amgen Receives Executive Summary from Independent Cochrane Collaboration Review of ESAs in Oncology

Wed, 01 Oct 2008 15:15:47 GMT

THOUSAND OAKS, Calif., Sep 30, 2008 (BUSINESS WIRE) -- Amgen Inc., (NASDAQ: AMGN) announced it has received a summary of preliminary results from the Cochrane Collaboration's independent meta-analysis of patient-level data from previously conducted,...

ImmunoVaccine Technologies' DepoVax Shows Positive Results for Cancer and Infectious Diseases

Wed, 01 Oct 2008 14:25:10 GMT

HALIFAX, Oct. 1 /PRNewswire/ -- ImmunoVaccine Technologies' (IVT) patented depot vaccine formulation, DepoVax(TM) is showing positive pre-clinical results, with single-dose efficacy achieved in therapeutic cancer and several infectious disease...

Critical Pharmaceuticals Enter Sustained Release hGH Arena

Wed, 01 Oct 2008 14:15:03 GMT

Preclinical Results of New Somatropin Formulation Demonstrate Advantages Over Existing Once-Daily Product NOTTINGHAM, England, October 1/PRNewswire/ -- Critical Pharmaceuticals, the Nottingham, UK-based speciality pharmaceuticals company, today...

Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien Study

Wed, 01 Oct 2008 14:10:14 GMT

ATLANTA, Oct. 1 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported the interim month six...

FDA Analysis Shows Cholesterol Lowering Medications Do Not Increase the Risk of "Lou Gehrig's Disease"

Tue, 30 Sep 2008 15:10:06 GMT

Agency recommends no change in prescribing and use of statins ROCKVILLE, Md., Sept. 29, 2008--A U.S. Food and Drug Administration's analysis provides new evidence that the use of statins does not increase incidence of amyotrophic lateral sclerosis...

VEGF Trap-Eye Final Phase 2 Results in Age-related Macular Degeneration Presented at 2008 Retina Society Meeting

Mon, 29 Sep 2008 16:15:35 GMT

Regression of total active lesion caused by wet AMD reported SCOTTSDALE, Ariz., Sept. 28, 2008--(BUSINESS WIRE)--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare AG announced that VEGF Trap-Eye achieved durable improvements...